Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Shares Gap Down – Should You Sell?

Bayer Aktiengesellschaft (OTCMKTS:BAYRY)’s stock price gapped down prior to trading on Tuesday. The stock had previously closed at $14.46, but opened at $13.92. Bayer Aktiengesellschaft shares last traded at $13.8810, with a volume of 22,926 shares trading hands.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on BAYRY. Zacks Research upgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 10th. Deutsche Bank Aktiengesellschaft upgraded Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a report on Thursday, July 2nd. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy”.

Bayer Aktiengesellschaft Stock Performance

The firm’s fifty day moving average is $14.02 and its 200 day moving average is $12.47. The firm has a market capitalization of $54.59 billion, a price-to-earnings ratio of -27.24, a PEG ratio of 2.15 and a beta of 0.56. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.04 and a quick ratio of 0.67.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last released its quarterly earnings data on Tuesday, August 4th. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.06. Bayer Aktiengesellschaft had a negative net margin of 3.80% and a positive return on equity of 16.77%. The firm had revenue of $12.53 billion for the quarter, compared to analyst estimates of $12.31 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. On average, analysts predict that Bayer Aktiengesellschaft will post 1.28 EPS for the current fiscal year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a Germany-based life science company focused on health care and agriculture. Through its Pharmaceuticals, Consumer Health and Crop Science businesses, the company develops and markets products intended to improve human health, everyday self-care and agricultural productivity.

Bayer’s Pharmaceuticals business provides prescription medicines in areas such as cardiovascular disease, women’s health, oncology and specialty medicine. Its Consumer Health division offers nonprescription products in categories including pain relief, nutritional supplements, dermatology and allergy care, with brands such as Aspirin and Claritin.